Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy (Endymion)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03635073
Recruitment Status : Recruiting
First Posted : August 17, 2018
Last Update Posted : June 11, 2019
Sponsor:
Collaborator:
Ovid Therapeutics Inc.
Information provided by (Responsible Party):
Takeda

Brief Summary:
The main purpose of this study is to investigate the long-term safety and tolerability of TAK-935/OV935 as an adjunctive therapy in patients with rare epilepsies.

Condition or disease Intervention/treatment Phase
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome, Dup15q Syndrome, CDKL5 Deficiency Disorder Drug: TAK-935 Phase 2

Detailed Description:

The drug being tested in this study is called TAK-935 (OV935). This global, open-label study will assess the safety and tolerability of TAK-935 for 2 years in patients who participated in previous short-term efficacy/safety studies of TAK-935. All patients will receive TAK-935 treatment.

Patients who rollover from previous blinded study will undergo up to 0 to 2 weeks of Dose Optimization Period (depending on the previous study) followed by 103-weeks of Maintenance Period. Patients who rollover from an open-label study will continue on their current dose for 103-weeks. There will be a 4-week safety follow-up after the last dose, including a 2-week dose tapering period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 176 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy
Actual Study Start Date : July 19, 2018
Estimated Primary Completion Date : March 21, 2023
Estimated Study Completion Date : April 21, 2023


Arm Intervention/treatment
Experimental: TAK-935
Treatment: 0 to 2 Weeks Dose Optimization Period followed by 103 weeks Maintenance Period.
Drug: TAK-935
TAK-935 tablets or mini-tablets.




Primary Outcome Measures :
  1. Incidence of Adverse Events [ Time Frame: up to Week 108 ]
  2. Change from Baseline in behavioral and adaptive functional measures using the Vineland Adaptive Behavior Scale (VABS) [ Time Frame: up to Week 108 ]
  3. Change from Baseline in behavior measures using total scores and subscale scores of the Aberrant Behavior Checklist-Community Edition (ABC-C) for patients ≥6 years of age [ Time Frame: up to Week 108 ]
  4. Change from Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) categorization based on Columbia Classification Algorithm of Suicide Assessment categories 1,2,3,4, and 7 for patients ≥6 years of age [ Time Frame: up to Week 108 ]

Secondary Outcome Measures :
  1. Change from Baseline in all seizure frequency [ Time Frame: up to Week 108 ]
  2. Change from Baseline in mean drop seizure frequency [ Time Frame: up to Week 108 ]
  3. Change from Baseline in mean convulsive [ Time Frame: up to Week 108 ]
  4. Change from Baseline in mean motor seizure frequency [ Time Frame: up to Week 108 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

1. Participants must have participated in a previous TAK-935 study and meet one of the following conditions:

  • Successfully completed a TAK-935 clinical study
  • In the opinion of the investigator, the participant has the potential to benefit from the administration of TAK-935

Exclusion Criteria:

  1. Clinically significant disease, that, in the investigator's opinion, precludes study participation
  2. Enrollment in any other clinical trial involving an investigational drug, device, or treatment in the past 90 days (with the exception of an antecedent study involving TAK-935)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03635073


Contacts
Layout table for location contacts
Contact: Ovid Call Center 646-661-7661 clinical@ovidrx.com

Locations
Layout table for location information
United States, Arizona
21st Century Neurology Recruiting
Phoenix, Arizona, United States, 85004
United States, Colorado
Colorado Children's Hospital 13123 East 16th Avenue Recruiting
Aurora, Colorado, United States, 80054
United States, Florida
Pediatric Neurology PA Recruiting
Orlando, Florida, United States, 32819
Medsol Clinical Research Center, Inc Recruiting
Port Charlotte, Florida, United States, 33952
University of South Florida Recruiting
Tampa, Florida, United States, 33606
United States, Georgia
Rare Disease Research, LLC Recruiting
Atlanta, Georgia, United States, 30318
Center for Rare Neurological Diseases Recruiting
Norcross, Georgia, United States, 30093
United States, Kentucky
Bluegrass Epilepsy Reseach Recruiting
Lexington, Kentucky, United States, 40504
United States, Minnesota
Minnesota Epilepsy Group PA Recruiting
Saint Paul, Minnesota, United States, 55102
United States, Missouri
Max Benzaquen, M.D., PC Recruiting
Chesterfield, Missouri, United States, 63017
Comprehensive Epilepsy Care Center For Children and Adults PC Completed
Saint Louis, Missouri, United States, 63141
United States, New Jersey
Northeast Regional Epilepsy Group Recruiting
Hackensack, New Jersey, United States, 07601
Children's Hospital at Saint Peter's University Hospital Recruiting
New Brunswick, New Jersey, United States, 08901
United States, South Carolina
Medical University of South Carolina - PPDS Recruiting
Charleston, South Carolina, United States, 29425
China
Peking University First Hospital Recruiting
Beijing, China, 100034
Children's Hospital of Fudan University Recruiting
Shanghai, China, 201102
Sponsors and Collaborators
Takeda
Ovid Therapeutics Inc.

Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT03635073     History of Changes
Other Study ID Numbers: TAK-935-18-001
U1111-1218-5515 ( Other Identifier: WHO )
First Posted: August 17, 2018    Key Record Dates
Last Update Posted: June 11, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Lennox Gastaut Syndrome
Epilepsies, Myoclonic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Epileptic Syndromes
Genetic Diseases, Inborn
Epilepsy, Generalized